Avery McKenna
YOU?
Author Swipe
View article: Gene therapies for sickle cell disease: Effectiveness and value
Gene therapies for sickle cell disease: Effectiveness and value Open
DISCLOSURES: Drs. Nikitin, McKenna, Rind, Nhan, and Pearson report grants from Arnold Ventures, grants from Blue Cross Blue Shield of MA, grants from California Healthcare Foundation, grants from The Commonwealth Fund, grants from The Patr…
View article: Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value
Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value Open
DISCLOSURES: Ms McKenna, Dr Lin, Dr Whittington, Mr Nikitin, Ms Herron-Smith, Dr Campbell, and Dr Peterson report grants from Arnold Ventures, grants from Blue Cross Blue Shield of MA, grants from California Healthcare Foundation, grants f…
View article: The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council Open
DISCLOSURES: Funding for this summary was contributed by Blue Cross Blue Shield of MA, California Healthcare Foundation, The Patrick and Catherine Weldon Donaghue Medical Research Foundation, Arnold Ventures, and Kaiser Foundation Health P…
View article: Decision letter for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"
Decision letter for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States" Open
About ICERThe Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to…
View article: Review for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"
Review for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States" Open
About ICERThe Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to…
View article: Review for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States"
Review for "Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States" Open
About ICERThe Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to…
View article: The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD
The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD Open
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic…
View article: The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer
The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer Open
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic…